Introduction: Insulin secretory defects are a key feature in the pathophysiology of type 2
diabetes (T2D). Classical insulin-secreting agents such as sulfonlyureas stimulate insulin …

Current treatments for non-insulin dependent diabetes mellitus (NIDDM) remain far from
ideal. The universal finding of islet dysfunction characterised by the absence of first phase …

Type 2 diabetes is a progressive chronic disease resulting from a dynamic interaction
between defects in insulin secretion and insulin action. New molecules have recently been …

Existing oral insulin secretagogues, sulphonylureas, are associated with hyperinsulinaemia,
risk of hypoglycaemia and weight gain. Furthermore, they are not able to offer durable …

Diabetes mellitus (DM) results from defects in insulin secretion (type 1) or insulin resistance
(type 2). Insulin is used to manage type 1 DM, and oral hypoglycemic agents are used to …

Insulin secretagogues including sulfonylureas, glinides and incretin‐related drugs such as
dipeptidyl peptidase 4 (DPP‐4) inhibitors and glucagon‐like peptide‐1 receptor agonists are …

Secretagogues are a class of agents that achieve their hypoglycemic effects through
stimulating insulin release. The oldest drugs in this class, sulfonylureas, are a fundamental …

Diabetes mellitus was considered a fatal malady until the discovery, extraction and
commercial availability of insulins. Numerous other classes of drugs ranging from …

Type 2 diabetes is characterised by insulin resistance and progressive β-cell dysfunction
(which leads to hyperglycaemia), the risk of progressive worsening of glycaemic control and …

The treatment of type 1 diabetes mellitus consists of external replacement of the functions of
β cells in an attempt to achieve blood levels of glucose as close to the normal range as …